Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

NCT00368329 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Esophageal Neoplasms
Carcinoma, Squamous Cell
Adenocarcinoma
Esophageal Cancer

Interventions

DRUG: Capecitabine (Xeloda)
DRUG: [18-F] Fluorodeoxyglucose (FDG)
DRUG: 5-Fluorouracil (5-FU)
DRUG: Carboplatin

Sponsor

Stanford University